tmk result in-lin midpoint
tmk oper ep y/i mostli consist
estim consensu life sale declin y/i outlook
meanwhil strong health net sale growth y/i exceed project
tmk narrow oper ep guidanc
notabl midpoint remain unchang impli y/i ep growth
larg driven benefit us corpor tax reform tmk repurchas
share mostli in-lin estim
life insur underwrit result in-lin expect sale miss
project life underwrit incom grew y/i consist
outlook life underwrit margin slightli better expect
year ago life net sale decreas y/i vs outlook mostli driven
decreas direct respons sale notabl tmk anticip life direct
respons direct-to-consum distribut channel sale return growth
point refer life direct respons sale declin
also expect declin respons elev claim experi
insur result mostli consist expect
underwrit incom y/i line outlook health
underwrit margin slightli estim year
ago net sale increas y/i exceed outlook
adjust ep result chang ep
estim tmk strong franchis middle-market life supplement
health insur us howev dont see much upsid ep expect
next year result slow premium growth stabl margin
view tmk overvalu ep estim book valu ex-aoci
rel roe profil
tmk quarterli annual ep usd
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
underweight torchmark strong franchis
middle-market life supplement health
insur us howev see much
upsid ep expect next year
result slow premium growth stabl
tmk averag roe strong earn
growth low volatil view tmk upsid
scenario base ep
risk thesi includ slower-than-anticip
econom recoveri impact low interest rate
regulatori risk view tmk downsid case
ep
continu next page
mil except per shry/i underwrit margin excess invest incom ep valu ex aoci chg actualin mil except per shry/i sale ex part sale chg actual barclay torchmark corp
mil except per polici acquisit segment underwrit invest requir interest net polici interest excess invest compani oper oper incom stock compens compens expens net oper incom continu oper uilic medicar part d- net oper incom capit gain loss capit gain loss discontinu ops- loss dispos discontinu ops- part adjustment- tax settlements- net oper incom continu oper incom dilut share per ratio total benefit oper profit oper profit percent excess invest oper earn continu op ep continu valu per common valu per share ex unreal inv gains/ loss qtr chang book valu per share ex unreal return return equiti return equiti ex unreal tax capit exclud reval invest portfolio yield share amt share amt common capit capit return normal annual barclay torchmark corp
jay gelb cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
barclay bank plc and/or affili lead manag co-lead manag publicli disclos offer secur issuer
 employe non-execut director barclay bank plc and/or affili director issuer
cd barclay bank plc and/or affili market-mak debt secur issu issuer
ce barclay bank plc and/or affili market-mak equiti secur issu issuer
barclay bank plc and/or affili receiv compens invest bank servic issuer past month
 barclay bank plc and/or affili expect receiv intend seek compens invest bank servic issuer
within next month
fa barclay bank plc and/or affili benefici own class equiti secur issuer calcul accord
us regul
fb barclay bank plc and/or affili benefici own long posit class equiti secur issuer
calcul accord eu regul
fc barclay bank plc and/or affili benefici own short posit class equiti secur issuer
calcul accord eu regul
gd one analyst fundament credit coverag team member household financi interest debt
equiti secur issuer
ge one analyst fundament equiti coverag team member household financi interest debt
equiti secur issuer
 issuer benefici own class common equiti secur barclay plc
barclay bank plc and/or affili parti agreement issuer provis financi servic barclay bank plc and/or
